Publications by authors named "R S Apte"
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases.
Invest Ophthalmol Vis Sci
January 2025
Ever since the US Food and Drug Administration (FDA) approved the first vascular endothelial growth factor (VEGF) antagonist 2 decades ago, inhibitors of VEGF have revolutionized the treatment of a variety of ocular disorders involving pathologic neovascularization and retinal exudation. In this perspective, we evaluate the current status of anti-VEGF therapies and the real-world challenges encountered with maintaining therapeutic outcomes. Finally, we describe novel VEGF-based and combinatorial approaches that are in clinical development.
View Article and Find Full Text PDFArticle Synopsis
- Biosimilars like MYL-1701P, a version of aflibercept, offer potentially cheaper options for treating diabetic macular edema (DME), but their efficacy and safety compared to the original have not been fully studied.
- A randomized double-masked trial across multiple countries involved 355 participants with DME to compare MYL-1701P and aflibercept, focusing on vision improvement and side effects over a year.
- Results showed similar improvements in visual acuity between the two treatments after 8 weeks, with MYL-1701P achieving an adjusted mean difference of just 0.04 letters from aflibercept, indicating comparable effectiveness.
Cholesterol Accumulation Promotes Photoreceptor Senescence and Retinal Degeneration.
Invest Ophthalmol Vis Sci
August 2024
Purpose: Dysregulated cholesterol metabolism is critical in the pathogenesis of AMD. Cellular senescence contributes to the development of numerous age-associated diseases. In this study, we investigated the link between cholesterol burden and the cellular senescence of photoreceptors.
View Article and Find Full Text PDF